Organon Discusses Asenapine Study Results

Organon’s asenapine was shown to be effective and well tolerated in patients with acute schizophrenia, according to a six-week study published in the Journal of Clinical Psychiatry.

In the study, 174 patients were randomized to a twice-daily, 5-mg dose of asenapine; a twice-daily, 3-mg dose of risperidone; or placebo for six weeks. Asenapine was more effective than placebo in improving both positive and negative symptoms associated with schizophrenia.

The difference was seen starting at the second week of treatment, Organon said.